Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SOCS2
REST API REST API
Homo sapiens
SOCS2 is differentially expressed in 358 experiments: 140 organism parts: prostate, uterus, ... (138 more);, 172 disease states: normal, chronic myelogenous leukemia, ... (170 more);, 115 cell types 455 cell lines 57 compound treatments and 76 other conditions.
Synonyms CIS2, SSI-2, SOCS-2, STATI2, Cish2, SSI2
Orthologs Q4H2S6_CIOIN (Ciona intestinalis)   Q8AYA6_CHICK (Gallus gallus)   socs2 (Danio rerio)   SOCS2_BOVIN (Bos taurus)   Socs2 (Rattus norvegicus)   socs2 (Xenopus laevis)   Q1ZZT6_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term regulation of signal transduction, insulin-like growth factor receptor binding, regulation of JAK-STAT cascade, protein binding, cytoplasm, negative regulation of signal transduction, anti-apoptosis, aging, SH3/SH2 adaptor activity, regulation of cell growth, JAK-STAT cascade, prolactin receptor binding, growth hormone receptor binding, JAK pathway signal transduction adaptor activity, response to peptide hormone stimulus, growth hormone receptor signaling pathway, response to estradiol stimulus, cellular response to hormone stimulus, intracellular signal transduction
InterPro Term SH2, SOCS_C
UniProt Accession O14508, B4DMW5, A8K3D1, F8VU91, F8VRV3, F8VS53
Search EB-eye ENSG00000120833
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-2549, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (52 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MCF-7
1
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
AGS
2
E-MTAB-37, E-GEOD-15460
DU145
2
E-GEOD-17482, E-GEOD-20089
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
449 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (59 experiments)

Factor Value U/D Experiments
plasma cell
2
E-GEOD-6691, E-MEXP-2360
macrophage
2
E-GEOD-5099, E-GEOD-360
CD34+
2
E-AFMX-5, E-TABM-145
T-cell
1
E-GEOD-10820
normal
1
E-GEOD-6883
mature monocyte derived dendritic cell
1
E-GEOD-4984
109 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (70 experiments)

Factor Value U/D Experiments
chronic myelogenous leukemia
4
E-MTAB-62, E-MTAB-37, E-GEOD-96, E-GEOD-5550
chronic lymphocytic leukemia
3
E-GEOD-6691, E-GEOD-2466, E-MTAB-37
prostate carcinoma
3
E-MEXP-2034, E-GEOD-7307, E-GEOD-96
chronic myelogenous leukemia K562
2
E-AFMX-5, E-TABM-145
lung adenocarcinoma
2
E-MEXP-231, E-GEOD-2514
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
166 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-4668, E-GEOD-5741, E-TABM-782, ... (35 experiments)

Factor Value U/D Experiments
none
4
8
E-MEXP-1601, E-MEXP-1958, E-GEOD-2803, E-GEOD-20719, E-TABM-782, ... (12 experiments)
control
1
E-GEOD-3284
galectin-1
1
E-GEOD-4984
dihydrotestoterone
1
E-GEOD-7708
oligomycin
1
E-MEXP-2285
propofol
1
E-GEOD-4386
51 more value(s).


Biosource provider

studied in E-GEOD-20559

Factor Value U/D Experiments
Cooperative Human Tissue Network (CHTN)
1
1
E-GEOD-20559


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-36, E-MEXP-1251, E-GEOD-2034, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-MEXP-480, E-GEOD-3325, E-GEOD-2509, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, E-TABM-263, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (30 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-1309, E-GEOD-22152, E-GEOD-1493, ... (11 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-20037 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-23984, ... (6 experiments)

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922

Processing time: 0.564 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM